Oncotelic Therapeutics, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
OQB
Seymour Howard Fein, CRO/CMO of Oncotelic Therapeutics, Inc., received 250 shares of common stock on July 10, 2026.
OQB
Steven W King, a Director of Oncotelic Therapeutics, Inc., received 250 shares of common stock on July 10, 2026.
OQB
Anthony E Maida Iii, DIRECTOR AND CMO - TRANS. MED. and a Director of Oncotelic Therapeutics, Inc., received 1,500 shares of common stock on July 10, 2026.
OQB
Saran Saund, CBO of Oncotelic Therapeutics, Inc., received 1,500 shares of common stock on July 10, 2026.
OQB
Amit B. Shah, CFO of Oncotelic Therapeutics, Inc., received 1,500 shares of common stock on July 10, 2026.
OQB
Vuong Trieu, CHAIRMAN AND CEO, a Director and 10% owner of Oncotelic Therapeutics, Inc., received 2,000 shares of common stock on July 10, 2026.
OQB
Form 4: Oncotelic Director Buys Shares
Oncotelic Therapeutics, Inc. director Vuong Trieu purchased 240,000 shares of common stock on July 1, 2026.
OQB
Oncotelic Therapeutics, Inc. CEO Vuong Trieu has acquired a significant number of company shares through open market purchases.
OQB
Chairman and CEO Vuong Trieu acquired 335,759 shares of Oncotelic Therapeutics, Inc. through open market purchases.
OQB
Oncotelic Therapeutics' Chairman and CEO, Vuong Trieu, received 4,426 shares of Series A Convertible Preferred Stock as compensation for achieving performance milestones.
OQB
Oncotelic Therapeutics' Chairman and CEO, Vuong Trieu, received 4,065 shares of Series A Convertible Preferred Stock, convertible into 4,065,000 common shares, as compensation for achieving performance milestones.
OQB
Oncotelic Therapeutics, Inc. CEO and Chairman, Vuong Trieu, has increased his direct beneficial ownership in the company through open market purchases of common stock.
OQB
Oncotelic Therapeutics' CEO, Vuong Trieu, has increased his holdings in the company by purchasing 346,844 shares of common stock on the open market between January 29 and January 31, 2025.
OQB
Oncotelic Therapeutics CEO, Trieu Vuong, purchased 298,499 shares of common stock at $0.0289 per share on November 22, 2024.
OQB
Oncotelic Therapeutics' CEO, Trieu Vuong, purchased 500,000 shares of the company's common stock at $0.02 per share on August 23, 2024.